苏州若弋生物科技

Ruoyi Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of next-generation recombinant protein drugs. The company utilizes its proprietary Sortase-mediated protein ligation platform to engineer complex biologics, including recombinant botulinum toxins and protein-drug conjugates (PDCs). Their lead candidate, RY01, is a recombinant botulinum toxin type A currently in clinical development for medical aesthetic indications such as glabellar lines. Ruoyi's technology aims to overcome the limitations of traditional botulinum toxins by providing higher purity, improved safety profiles, and the potential for modified therapeutic properties. The company is also exploring the application of its platform in neurology and oncology, supported by a strong investor base including Decheng Capital and Legend Capital.